- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Mankind Pharma’s 11% stake sale to PE investors gets a CCI nod
Private equity investors Cairnhill CIPEF Ltd (CCL) and Cairnhill CGPE Ltd (CGL) would acquire 11 per cent stake of Mankind PharmaCairnhill CIPEF Ltd (CCL) and Cairnhill CGPE Ltd (CGL), Mauritius based private equity investors would acquire 11 per cent stake in Mankind Pharma. Strategically advised by the Capital Group, a foreign institutional investor in India, the two companies have no...
Cairnhill CIPEF Ltd (CCL) and Cairnhill CGPE Ltd (CGL), Mauritius based private equity investors would acquire 11 per cent stake in Mankind Pharma. Strategically advised by the Capital Group, a foreign institutional investor in India, the two companies have no earlier stake in the pharmaceutical industry in the country. CCL and CGL will be acquiring shareholding in the pharma company by acquiring stakes from Monet Ltd and one Dinaz Kaul.
Approving the deal, the Competition Control of India has said the transaction is not likely to have any appreciable adverse effect on competition in India.
As reported by PTI,
Citing details provided by the two private equity players, Competition Commission of India (CCI) said neither they nor the funds managed and advised by Capital Group hold any investments in pharmaceutical sector in the country.
"Thus, there is no horizontal overlap between investors and the target (Mankind). Further, since the investors do not have any investment in pharmaceutical sector in India, there is no possibility of any vertical foreclosure resulting from the proposed combination," CCI said in its order dated June 25 and made public today
Mankind is into the business of manufacturing and trading of pharmaceutical and healthcare products. The company has products in therapeutic areas ranging from antibiotic and antifungal compounds, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications. It is reported to be the seventh-largest drug maker of India
Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country.She is a member of the Association of Healthcare Journalists. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751